Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.07.2021 | Case report

Clobetasol/dupilumab/interferon-α-2a

Conjunctivitis, off-label use and ineffectiveness: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Steck O, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sezary syndrome. Journal of the European Academy of Dermatology and Venereology 35: 1331-1337, No. 6, Jun 2021. Available from: URL: http://doi.org/10.1111/jdv.17001 Steck O, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sezary syndrome. Journal of the European Academy of Dermatology and Venereology 35: 1331-1337, No. 6, Jun 2021. Available from: URL: http://​doi.​org/​10.​1111/​jdv.​17001
Metadaten
Titel
Clobetasol/dupilumab/interferon-α-2a
Conjunctivitis, off-label use and ineffectiveness: case report
Publikationsdatum
01.07.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-99045-7

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Rituximab

Case report

Multiple drugs